0001680048 false 12/31 0001680048 2021-06-17 2021-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 17, 2021

 

Mustang Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38191   47-3828760
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

377 Plantation Street

Worcester, Massachusetts 01605

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   MBIO   NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

As described under Item 5.07 of this report, on June 17, 2021, the stockholders of the Mustang Bio, Inc. (“Mustang”) voted at the 2021 Annual Meeting to approve an amendment to Mustang’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 25,000,000 shares, bringing the total number of authorized shares of common stock to 150,000,000 shares (the “Amendment”).

 

On June 17, 2021, following the 2021 Annual Meeting, the Company filed a certificate of amendment (the “Certificate”) giving effect to the Amendment with the Secretary of State of the State of Delaware. A copy of the Certificate is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.03.

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

Mustang held its annual meeting of stockholders on June 17, 2021 by means of an online virtual meeting platform at 3:00 p.m. Eastern Time. Stockholders representing 67,445,018, or 77.70% of the 86,797,943 shares entitled to vote were represented in person or by proxy constituting a quorum. At the annual meeting, the following five proposals were approved: (i) the election of six directors to hold office until the 2022 annual meeting; (ii) the ratification of the appointment of BDO USA, LLP as Mustang’s independent registered public accounting firm for the year ending December 31, 2021; (iii) an amendment to Mustang’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 25,000,000 shares from 125,000,000 to 150,000,000; (iv) an amendment to Mustang’s 2016 Incentive Plan to increase the shares of common stock available for issuance under the 2016 Incentive Plan by 3,000,000 shares; and (v) an amendment to Mustang’s 2019 Employee Stock Purchase Plan to increase the shares of common stock available for issuance under the 2019 Employee Stock Purchase Plan by 600,000 shares. Proposal 3, a shareholder proposal to amend the Company’s articles and/or bylaws to require majority vote in director elections, was not approved. The six proposals are described in detail in Mustang’s definitive proxy statement dated April 30, 2021 for the annual meeting.

 

Proposal 1

 

The votes with respect to the election of six directors to hold office until the 2022 annual meeting were as follows:

 

Director  For  % Voted For  Withheld  % Voted Withheld
Michael S. Weiss  23,856,742  66.90%  11,803,741  33.10%
Lindsay A. Rosenwald, M.D.  23,831,511  66.83%  11,828,972  33.17%
Neil Herskowitz  25,810,625  72.38%  9,849,858  27.62%
Manuel Litchman, M.D.  27,106,829  76.01%  8,553,654  23.99%
Adam Chill  29,709,544  83.31%  5,950,939  16.69%
Michael Zelefsky, M.D.  29,737,383  83.39%  5,923,100  16.61%

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of re-electing the six directors named above.

 

Proposal 2

 

The votes with respect to the ratification of BDO USA, LLP as Mustang’s independent registered accounting firm for the year ending December 31, 2021 was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 66,561,128    431,301    452,589    0 

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of ratifying the appointment of BDO USA, LLP as Mustang’s independent registered public accounting firm for the year ending December 31, 2021.

 

Proposal 3

 

The votes with respect to a shareholder proposal to amend Mustang’s articles of incorporation and/or bylaws to require a majority vote in director elections was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 17,673,865    17,766,815    219,803    31,784,535 

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares against the shareholder proposal to amend Mustang’s articles of incorporation and/or bylaws to require a majority vote in director elections.

 

 

 

 

Proposal 4

 

The votes with respect to the approval of an amendment to Mustang’s Amended and Restated Certificate of Incorporation was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 60,924,543    5,992,543    527,932    0 

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of the amendment to Mustang’s Amended and Restated Certificate of Incorporation.

 

Proposal 5

 

The vote with respect to the approval of an amendment to Mustang’s 2016 Incentive Plan was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 34,057,508    1,468,448    134,527    31,784,535 

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of the amendment to Mustang’s 2016 Incentive Plan.

 

Proposal 6

 

The vote with respect to the approval of an amendment to Mustang’s 2019 Employee Stock Purchase Plan was as follows:

 

Total Votes For   Total Votes Against   Abstentions   Broker Non-Votes 
 34,445,971    1,159,450    55,062    31,784,535 

 

In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of the amendment to Mustang’s 2019 Employee Stock Purchase Plan.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are filed as part of this report:

 

Exhibit
Number
  Description
     
3.1   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Mustang Bio, Inc.
     
10.1   Second Amendment to Mustang Bio, Inc. 2016 Incentive Plan
     
10.2   Amendment to Mustang Bio, Inc. 2019 Employee Stock Purchase Plan
     
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  

Date: June 22, 2021 Mustang Bio, Inc.  
  (Registrant)  
       
       
  By: /s/ Manuel Litchman, M.D.  
    Manuel Litchman, M.D.  
    President and Chief Executive Officer